SEATTLE, April 04, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp.’s (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQB:LXRP) DehydraTECH™ which represents a breakthrough in cannabinoid drug delivery. Lexaria’s DehydraTECH™ is technology that promotes a molecular association between cannabinoids and certain fatty acid compounds that are known to have palatability and bio-absorption enhancing properties. This combination, in turn, results in improved cannabinoid taste, bioavailability and speed of effectiveness.
In the quickly expanding legal cannabis industry, effective delivery of the drug is an ongoing problem. Many consumers have taken to edible products as a healthier alternative to smoking, but there are still key issues with bioavailability and taste when infusing cannabinoids. Other delivery methods have gained in popularity as well, including topical creams and lotions. In addition to improving intestinal bio-absorption by as much as five to ten times in as little as 15 minutes, new laboratory study data has shown that the DehydraTECH™ technology is just as promising when it comes to transdermal applications.
Transdermal Applications
In March, the company announced the results from its first laboratory study of DehydraTECH™ on human skin at a California-based laboratory specializing in Franz diffusion cell skin permeability testing. Researchers compared the technology with two leading skin penetration enhancers, looking for penetration time, absorption quantity, and peak amounts of CBD absorbed into and through the skin at multiple testing intervals over 48 hours.
The researchers found that DehydraTECH™ was the fastest acting for absorption into the skin and demonstrated the highest overall average quantity of CBD delivered through the skin. In fact, the technology outperformed competing products by as much as 225%. The technology also lacked any odor, even without the use of perfumes, contrary to other cannabinoid industry products that can be quite odoriferous without the use of masking perfumes.
“We have theorized for some time that our DehydraTECH™ delivery system might have positive effects on skin-based delivery complementing its already commercialized gastro-intestinal product applications,” said Lexaria President John Docherty. “The first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications.”
Building an IP Portfolio
Lexaria has already begun to commercialize the DehydraTECH™ delivery system, as well as build up its patent portfolio. Earlier this year, the company entered into two licensing agreements for the innovative platform with a cannabis edibles maker and a Canadian cannabis chocolate manufacturer. Under these agreements, the company has licensed out its technology for the development of edible products in exchange for licensing fees and royalties.
On March 22, the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office providing for a “composition of matter” claims that protect the specific combination of substances which enable improved taste and bio-absorption. This adds to the company’s existing “method of use” patent that had previously been granted, further protects its delivery system, and opens the door to further commercialization.
“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said Mr. Docherty. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed.”
Looking Ahead
Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP) represents a compelling investment opportunity in the cannabis industry. By solving a key issue facing many edibles manufacturers, the company hopes to license its technology to a growing number of companies in exchange for licensing fees and royalties. These high-margin revenues could unlock significant value for shareholders over the long-term.
For more information, visit the company’s website or download their investor presentation.
Please follow the link to read the full article: http://www.cannabisfn.com/lexaria-expands-transdermal-grows-licensing-revenue/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
Frank Lane
206-369-7050
Flane@cannabisfn.com